Naltrexone
- Generic Name
- Naltrexone
- Brand Names
- Contrave, Embeda, Vivitrol
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23NO4
- CAS Number
- 16590-41-3
- Unique Ingredient Identifier
- 5S6W795CQM
- Background
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
- Indication
Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
- Associated Conditions
- Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain
- Associated Therapies
- -
Stress, Hormones, and Eating
- Conditions
- Interventions
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 42
- Registration Number
- NCT01175512
Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+
- Conditions
- Interventions
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- The Ojai Foundation
- Target Recruit Count
- 171
- Registration Number
- NCT01174914
- Locations
- 🇲🇱
University Hospital of Point G, Bamako, Mali
Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder
- Conditions
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2010-05-28
- Lead Sponsor
- Central Institute of Mental Health, Mannheim
- Target Recruit Count
- 30
- Registration Number
- NCT01133301
- Locations
- 🇩🇪
Department of Psychiatry and Psychotherapy, University of Freiburg, Freiburg, Baden Württemberg, Germany
Medication and Counseling for Controlled Drinking
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Research Foundation for Mental Hygiene, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT01115894
- Locations
- 🇺🇸
Columbia Addiction Services and Psychotherapy Intervention Research, New York, New York, United States
Investigation of Naltrexone for Pathological Gambling
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 9
- Registration Number
- NCT01057862
- Locations
- 🇺🇸
Connecticut DMHAS Problem Gambling Services and Bettor Choice Programs, New Haven, Connecticut, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Naltrexone and Hypoglycemia in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 29
- Registration Number
- NCT01053078
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Naltrexone for Impulse Control Disorders in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 50
- Registration Number
- NCT01052831
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2014-06-10
- Lead Sponsor
- State University of New York at Buffalo
- Registration Number
- NCT01015066
- Locations
- 🇺🇸
UB Department of Family Medicine, Buffalo, New York, United States
Study of Naltrexone for Methamphetamine Addiction
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2013-05-31
- Target Recruit Count
- 22
- Registration Number
- NCT00984360
- Locations
- 🇺🇸
Addiction & Pharmacology Research Laboratory, San Francisco, California, United States
Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment
- Conditions
- Interventions
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Brown University
- Target Recruit Count
- 150
- Registration Number
- NCT00938886
- Locations
- 🇺🇸
Brown University, Providence, Rhode Island, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.